It explains, as discussed above, why numerous candidate AD drugs showed no efficacy in human clinical trials (due to the occurrence of AβPP-independent production of iAβ) yet were very effective in animal studies (due to the lack of the second AD stage, i.e., the absence of the generation of iAβ independently of AβPP in animal models). The gene discussed is APP; the disease is Alzheimer disease.